A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
Information source: Bayer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Contraception
Intervention: Ethinylestradiol (Drug); drospirenone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Schering Pharma AG, Germany, Medical Affairs Region Asia/Pacific, Study Director, Affiliation: +65 6511 6194
Summary
The purpose of this study is to compare the efficacy and safety of Yasmin® and Marvelon® in
Chinese women requiring contraception
Clinical Details
Official title: An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles
Study design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Cycle control from randomization to cycle 13
Secondary outcome: Contraceptive reliabilityQuality of life
Detailed description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility
Minimum age: 20 Years.
Maximum age: 35 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Healthy Chinese female requesting contraceptives
Exclusion Criteria:
- Vascular, metabolic, hepatic, renal, oncologic and other diseases
Locations and Contacts
Additional Information
Starting date: November 2003
Last updated: May 8, 2007
|
